• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

China CDC Wkly . Genomic Surveillance for SARS-CoV-2 - China, September 26, 2022 to January 29, 2023

tetano

Editor, Senior Moderator
China CDC Wkly


. 2023 Feb 17;5(7):143-151.
doi: 10.46234/ccdcw2023.026.
Genomic Surveillance for SARS-CoV-2 - China, September 26, 2022 to January 29, 2023


Shiwen Wang[SUP] 1 2 [/SUP], Peihua Niu[SUP] 1 [/SUP], Qiudong Su[SUP] 1 [/SUP], Xiaozhou He[SUP] 1 [/SUP], Jing Tang[SUP] 1 [/SUP], Ji Wang[SUP] 1 [/SUP], Yenan Feng[SUP] 1 2 [/SUP], Cao Chen[SUP] 1 [/SUP], Xiang Zhao[SUP] 1 [/SUP], Zhixiao Chen[SUP] 1 [/SUP], Wenling Wang[SUP] 1 [/SUP], Zeyuan Yin[SUP] 1 [/SUP], Yuchao Wu[SUP] 1 [/SUP], Changcheng Wu[SUP] 1 [/SUP], Lili Li[SUP] 1 [/SUP], Aili Cui[SUP] 1 [/SUP], Yan Zhang[SUP] 1 [/SUP], Caiyun Long[SUP] 1 [/SUP], Xiaoyu Yang[SUP] 1 [/SUP], Zhongxian Zhang[SUP] 1 [/SUP], Hong Bo[SUP] 1 [/SUP], Wenbo Xu[SUP] 1 2 [/SUP], Sars-CoV-Genome Working Group[SUP] 1 2 [/SUP]



Affiliations

Abstract

Introduction: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has generated 2,431 variants over the course of its global transmission over the past 3 years. To better evaluate the genomic variation of SARS-CoV-2 before and after the optimization of coronavirus disease 2019 (COVID-19) prevention and control strategies, we analyzed the genetic evolution branch composition and genomic variation of SARS-CoV-2 in both domestic and imported cases in China (the data from Hong Kong and Macau Special Administrative Regions and Taiwan, China were not included) from September 26, 2022 to January 29, 2023.
Methods: Analysis of the number of genome sequences, sampling time, dynamic changes of evolutionary branches, origin, and clinical typing of SARS-CoV-2 variants submitted by 31 provincial-level administrative divisions (PLADs) and Xinjiang Production and Construction Corps (XPCC) was conducted to assess the accuracy and timeliness of SARS-CoV-2 variant surveillance.
Results: From September 26, 2022 to January 29, 2023, 20,013 valid genome sequences of domestic cases were reported in China, with 72 evolutionary branches. Additionally, 1,978 valid genome sequences of imported cases were reported, with 169 evolutionary branches. The prevalence of the Omicron variants of SARS-CoV-2 in both domestic and imported cases was consistent with that of international epidemic variants.
Conclusions: This study provides an overview of the prevalence of Omicron variants of SARS-CoV-2 in China. After optimizing COVID-19 prevention and control strategies, no novel Omicron variants of SARS-CoV-2 with altered biological characteristics or public health significance have been identified since December 1, 2022.

Keywords: COVID-19; Genomic Surveillance; SARS-CoV-2; variant.
 
Back
Top Bottom